Investigational drug · Phase 3
Taxane
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Breast Cancer; HER2-positive; Metastatic, Solid Tumors, Platinum-resistant Ovarian Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
5,823
Any phase or sponsor naming "Taxane"
First trial start
2021
Apr 26, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Taxane", any sponsor or status.
Conditions studied
As listed on its trial records.
- Breast Cancer; HER2-positive; Metastatic
- Solid Tumors
- Platinum-resistant Ovarian Cancer
- Platinum-refractory Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
- High-grade Serous Ovarian Cancer
- Endometrioid Ovarian Cancer
- Ovarian Clear Cell Carcinoma
Approved drugs for the same conditions: Breast cancer · Ovarian cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Taxane" as an intervention, largest first.
Lahey ClinicAcademic, hospital or other
NCT04110288 · 219,483 participants · Start Jan 1, 2017 · Primary completion Aug 30, 2019
Drug: Paclitaxel · For: Peripheral Vascular Disease
Sites: Burlington, Massachusetts
- Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug EfficacyPivotal-lookingActive, not recruiting
Medical Research CouncilGovernment (non-federal)
NCT00268476 · 11,992 participants · Start Jul 8, 2005 · Primary completion Mar 2026
Drug: Celecoxib; Docetaxel and 7 more · For: Prostate Cancer
Sites: Lausanne, Switzerland; Winterthur, Switzerland; Chur, Switzerland · 120 sites in all
Lahey ClinicAcademic, hospital or other
NCT04647643 · 8,000 participants · Start Nov 20, 2020 · Primary completion Dec 31, 2021
Drug: Paclitaxel · For: Peripheral Arterial Disease
Sites: Burlington, Massachusetts
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02194738 · 7,458 participants · Start Sep 26, 2014 · Primary completion Dec 3, 2025
Drug: Carboplatin; Cisplatin and 8 more · For: Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIA Lung Cancer AJCC v8 and 4 more
Sites: Birmingham, Alabama; Daphne, Alabama; Mobile, Alabama · 1,660 sites in all
- Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph NodesPivotal-lookingCompleted
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT00433589 · 6,600 participants (planned) · Start Feb 2007 · Primary completion Mar 2020
Drug: anthracycline-based; docetaxel and capecitabine and 2 more · For: Breast Cancer
Sites: Amsterdam, Netherlands
- Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph NodesPivotal-lookingCompleted
NSABP Foundation IncResearch network
NCT00003782 · 5,351 participants · Start Mar 1999 · Primary completion Dec 2008
Drug: cyclophosphamide; docetaxel and 1 more · For: Breast Cancer
Sites: Huntsville, Alabama; Anchorage, Alaska; Phoenix, Arizona · 157 sites in all
PfizerPfizer (PFE)
NCT05834348 · 5,279 participants · Start Jun 23, 2023 · Primary completion Jan 23, 2024
Drug: lorlatinib; crizotinib and 16 more · For: Non-Small Cell Lung Cancer
Sites: Oslo, Norway
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
- Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast CancerPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT00433511 · 4,994 participants · Start Nov 2, 2007 · Primary completion Jan 7, 2014
Drug: Bevacizumab; Cyclophosphamide and 2 more · For: Breast Adenocarcinoma
Sites: Anniston, Alabama; Birmingham, Alabama; Mobile, Alabama · 842 sites in all
- ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast CancerPivotal-lookingCompleted
Women's Cancer Study Group GmbHAcademic, hospital or other
NCT01779206 · 4,936 participants (planned) · Start May 2012 · Primary completion Sep 2019
Drug: Epirubicin; Cyclophosphamide and 2 more · For: Breast Cancer
Sites: Munich, Germany; Mönchengladbach, Germany
Newest research
PubMed records naming it or its code names, newest first.
- Metabolic engineering of Taxus chinensis suspension cell lines for overproduction of paclitaxel reveals insights into pathway regulation.
Newton CB, McKee MC, Harrison AM, et al. · Metab Eng 2027
- Mid- and Long-Term Risk of Venous Thromboembolism Among Female Breast Cancer Survivors: A Nationwide Cohort Study.
Kang J, Jung W, Kim B, et al. · Int J Cancer 2026
- Carborane-modified paclitaxel analogues: Position-dependent modulation of mitotic catastrophe and lysosomal function.
Rykowski S, Różycka D, Orlicka-Pocka M, et al. · Eur J Med Chem 2026
- Advances in neoadjuvant therapy for locally advanced head and neck squamous cell carcinoma (Review).
You H, Qin X, Fu S · Oncol Rep 2026
- TROP2 expression in gastric and GEJ adenocarcinomas: associations with clinicopathological features, biomarkers, and treatment outcomes.
Tong Y, Nakayama I, Sakamoto N, et al. · ESMO Gastrointest Oncol 2026
- [177Lu]Lu-PSMA-617 Plus Short-Course Priming With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Single-Arm Phase 2 Trial (Lu-PRIME).
Aggarwal P, Sood A, Satapathy S, et al. · Prostate 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.